About: Emylcamate

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed. A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:

Property	Value
dbo:abstract	Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed. A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established: Emylcamate also has a faster intra-parenteral onset than meprobamate, 3 minutes compared with 35. (en)
dbo:casNumber	78-28-4
dbo:chEBI	134769
dbo:chEMBL	2104208
dbo:drugbank	DB13572
dbo:fdaUniiCode	KCJ747D3R4
dbo:kegg	D07317
dbo:pubchem	6526
dbo:thumbnail	wiki-commons:Special:FilePath/Emylcamate.svg?width=300
dbo:wikiPageExternalLink	http://www.biam2.org/www/Sub2770.html http://www.revistapsiqrs.org.br/administracao/arquivos/10-698-olhando_para_tras.pdf http://ctdbase.org/detail.go%3Ftype=chem&acc=C100111 https://web.archive.org/web/20060721024711/http:/www.revistapsiqrs.org.br/administracao/arquivos/10-698-olhando_para_tras.pdf
dbo:wikiPageID	3493584 (xsd:integer)
dbo:wikiPageLength	3731 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1120611035 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Carbamates dbc:GABAA_receptor_positive_allosteric_modulators dbc:Muscle_relaxants dbr:Anxiolytic dbr:Therapeutic_index dbr:Muscle_relaxant dbc:Anxiolytics dbr:Median_lethal_dose dbr:Effective_dose_(pharmacology) dbr:Meprobamate dbr:Merck_&_Co.
dbp:atcPrefix	N05 (en)
dbp:atcSuffix	BC03 (en)
dbp:c	7 (xsd:integer)
dbp:casNumber	78 (xsd:integer)
dbp:chebi	134769 (xsd:integer)
dbp:chembl	2104208 (xsd:integer)
dbp:chemspiderid	6278 (xsd:integer)
dbp:drugbank	DB13572 (en)
dbp:h	15 (xsd:integer)
dbp:iupacName	3 (xsd:integer)
dbp:kegg	D07317 (en)
dbp:n	1 (xsd:integer)
dbp:o	2 (xsd:integer)
dbp:pubchem	6526 (xsd:integer)
dbp:smiles	O=CN (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	SLWGJZPKHAXZQL-UHFFFAOYSA-N (en)
dbp:unii	KCJ747D3R4 (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	455055546 (xsd:integer)
dbp:width	150 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Cite_journal dbt:Cite_web dbt:Drugbox dbt:GABAAR_PAMs dbt:Musculoskeletal-drug-stub dbt:Refbegin dbt:Refend dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Anxiolytics dbt:Anxiolytic-stub
dcterms:subject	dbc:Carbamates dbc:GABAA_receptor_positive_allosteric_modulators dbc:Muscle_relaxants dbc:Anxiolytics
gold:hypernym	dbr:Relaxant
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAnxiolytics yago:WikicatMuscleRelaxants yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:DrugOfAbuse103248958 yago:Matter100020827 yago:Medicine103740161 yago:MinorTranquilizer103771443 yago:MuscleRelaxant103800001 yago:PhysicalEntity100001930 yago:PsychotropicAgent104017429 yago:Relaxant104072811 dbo:Drug yago:Sedative-hypnotic104166841 yago:Sedative104166553 yago:Substance100020090 yago:Tranquilizer104470232 umbel-rc:DrugProduct
rdfs:comment	Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed. A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established: (en)
rdfs:label	Emylcamate (en)
owl:sameAs	freebase:Emylcamate yago-res:Emylcamate wikidata:Emylcamate dbpedia-hu:Emylcamate dbpedia-sh:Emylcamate dbpedia-sr:Emylcamate dbpedia-vi:Emylcamate https://global.dbpedia.org/id/3WSLk
prov:wasDerivedFrom	wikipedia-en:Emylcamate?oldid=1120611035&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Emylcamate.svg
foaf:isPrimaryTopicOf	wikipedia-en:Emylcamate
is dbo:wikiPageRedirects of	dbr:ATC_code_N05BC03 dbr:ATCvet_code_QN05BC03
is dbo:wikiPageWikiLink of	dbr:Carbamic_acid dbr:List_of_compounds_with_carbon_number_7 dbr:Depressant dbr:3-Methyl-3-pentanol dbr:ATC_code_N05BC03 dbr:ATCvet_code_QN05BC03 dbr:ATC_code_N05 dbr:C7H15NO2 dbr:List_of_drugs:_Em–Ep
is foaf:primaryTopic of	wikipedia-en:Emylcamate